Narrow-Spectrum Oxadiazole Antibacterials that Target Cell−Wall Septation in Clostridioides difficile and Spare the Gut Microbiota
- 11 November 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Recurrence of infection is a challenge in treatment of Clostridioides difficile infection (CDI), observed in 25% of patients. The first-line antibiotics disturb the gut microbiota, exacerbating the already disrupted commensal gut homeostasis and allow for C. difficile colonization. Narrow-spectrum antibiotics are critical for selective targeting of C. difficile while preserving beneficial gut flora, thereby mitigating recurrence. Our study investigates a novel class of highly selective, nitroimidazole-based oxadiazole antibacterials. We detail the chemical basis for their exceptional selectivity against C. difficile over commensal bacteria and elucidate their mechanism of action. Oxadiazole 2 inhibits penicillin-binding proteins 1 and 3 involved in septal peptidoglycan biosynthesis during vegetative cell division. We further demonstrate by whole-genome sequencing that treatment of mice with oxadiazole 2 does not disrupt the gut microflora and confers an impediment to colonization by C. difficile. This work is foundational for development of a new generation of narrow-spectrum therapeutics to combat CDI.Funding Information
- Eck Institute for Global Health, University of Notre Dame
- American Heart Association (25PRE1375230)
- National Institute of Allergy and Infectious Diseases (AI198244)
- National Institute of General Medical Sciences (T32 GM075762)
- National Institute of General Medical Sciences (T32 GM145773)
This publication has 44 references indexed in Scilit:
- Phosphorylation of Staphylococcus aureus β‐lactamase, a prerequisite to its sequestration on the cytoplasmic membraneProtein Science, 2025
- Stay on track — revelations of bacterial cell wall synthesis enzymes and things that go by single-molecule imagingCurrent Opinion in Microbiology, 2024
- A Potent and Narrow-Spectrum Antibacterial against Clostridioides difficile InfectionJournal of Medicinal Chemistry, 2023
- Microbiota DNA isolation, 16S rRNA amplicon sequencing, and bioinformatic analysis for bacterial microbiome profiling of rodent fecal samplesSTAR Protocols, 2022
- A cortex-specific penicillin-binding protein contributes to heat resistance in Clostridioides difficile sporesAnaerobe, 2021
- Continued decline in the prevalence of the Clostridioides difficile BI/NAP1/027 strain across the United States Veterans Health AdministrationDiagnostic Microbiology and Infectious Disease, 2021
- Analysis of the microbiome: Advantages of whole genome shotgun versus 16S amplicon sequencingBiochemical and Biophysical Research Communications, 2016
- Exploration of the structure–activity relationship of 1,2,4-oxadiazole antibioticsBioorganic & Medicinal Chemistry Letters, 2015
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidenceInternational Journal of Antimicrobial Agents, 2012